Curis (NASDAQ:CRIS – Get Free Report) and Soligenix (NASDAQ:SNGX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Profitability
This table compares Curis and Soligenix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curis | N/A | -2,365.94% | -200.88% |
| Soligenix | N/A | -180.25% | -107.46% |
Risk and Volatility
Curis has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.
Earnings and Valuation
This table compares Curis and Soligenix”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curis | $9.44 million | 0.09 | -$7.58 million | ($14.22) | -0.03 |
| Soligenix | $120,000.00 | 43.61 | -$11.08 million | ($0.98) | -0.36 |
Curis has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Curis and Soligenix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curis | 1 | 1 | 1 | 0 | 2.00 |
| Soligenix | 1 | 0 | 0 | 0 | 1.00 |
Curis presently has a consensus price target of $43.00, suggesting a potential upside of 10,462.52%. Given Curis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Curis is more favorable than Soligenix.
Institutional and Insider Ownership
30.0% of Curis shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Curis beats Soligenix on 8 of the 12 factors compared between the two stocks.
About Curis
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
